164 results on '"Snowdon, Claire"'
Search Results
2. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units
- Author
-
Love, Sharon B., Cafferty, Fay, Snowdon, Claire, Carty, Karen, Savage, Joshua, Pallmann, Philip, McParland, Lucy, Brown, Louise, Masters, Lindsey, Schiavone, Francesca, Hague, Dominic, Townsend, Stephen, Amos, Claire, South, Annabelle, Sturgeon, Kate, Langley, Ruth, Maughan, Timothy, James, Nicholas, Hall, Emma, Kernaghan, Sarah, Bliss, Judith, Turner, Nick, Tutt, Andrew, Yap, Christina, Firth, Charlotte, Kong, Anthony, Mehanna, Hisham, Watts, Colin, Hills, Robert, Thomas, Ian, Copland, Mhairi, Bell, Sue, Sebag-Montefiore, David, Jones, Robert, Parmar, Mahesh K. B., and Sydes, Matthew R.
- Published
- 2022
- Full Text
- View/download PDF
3. Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer
- Author
-
Snowdon, Claire, Kernaghan, Sarah, Moretti, Laura, Turner, Nicholas C., Ring, Alistair, Wilkinson, Katie, Martin, Sue, Foster, Stephanie, Kilburn, Lucy S., and Bliss, Judith M.
- Published
- 2022
- Full Text
- View/download PDF
4. Practical guidance for planning resources required to support publicly-funded adaptive clinical trials
- Author
-
Wason, James M. S., Dimairo, Munyaradzi, Biggs, Katie, Bowden, Sarah, Brown, Julia, Flight, Laura, Hall, Jamie, Jaki, Thomas, Lowe, Rachel, Pallmann, Philip, Pilling, Mark A., Snowdon, Claire, Sydes, Matthew R., Villar, Sofía S., Weir, Christopher J., Wilson, Nina, Yap, Christina, Hancock, Helen, and Maier, Rebecca
- Published
- 2022
- Full Text
- View/download PDF
5. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
- Author
-
Turner, Nicholas C, Kingston, Belinda, Kilburn, Lucy S, Kernaghan, Sarah, Wardley, Andrew M, Macpherson, Iain R, Baird, Richard D, Roylance, Rebecca, Stephens, Peter, Oikonomidou, Olga, Braybrooke, Jeremy P, Tuthill, Mark, Abraham, Jacinta, Winter, Matthew C, Bye, Hannah, Hubank, Michael, Gevensleben, Heidrun, Cutts, Ros, Snowdon, Claire, Rea, Daniel, Cameron, David, Shaaban, Abeer, Randle, Katrina, Martin, Sue, Wilkinson, Katie, Moretti, Laura, Bliss, Judith M, and Ring, Alistair
- Published
- 2020
- Full Text
- View/download PDF
6. Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project
- Author
-
Wilson, Nina, Biggs, Katie, Bowden, Sarah, Brown, Julia, Dimairo, Munyaradzi, Flight, Laura, Hall, Jamie, Hockaday, Anna, Jaki, Thomas, Lowe, Rachel, Murphy, Caroline, Pallmann, Philip, Pilling, Mark A., Snowdon, Claire, Sydes, Matthew R., Villar, Sofía S., Weir, Christopher J., Welburn, Jessica, Yap, Christina, Maier, Rebecca, Hancock, Helen, and Wason, James M. S.
- Published
- 2021
- Full Text
- View/download PDF
7. Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
- Author
-
Judson, Ian, Morden, James P, Kilburn, Lucy, Leahy, Michael, Benson, Charlotte, Bhadri, Vivek, Campbell-Hewson, Quentin, Cubedo, Ricardo, Dangoor, Adam, Fox, Lisa, Hennig, Ivo, Jarman, Katy, Joubert, Warren, Kernaghan, Sarah, López Pousa, Antonio, McNeil, Catriona, Seddon, Beatrice, Snowdon, Claire, Tattersall, Martin, Toms, Christy, Martinez Trufero, Javier, and Bliss, Judith M
- Published
- 2019
- Full Text
- View/download PDF
8. Testing approaches to sharing trial results with participants: The Show RESPECT cluster randomised, factorial, mixed methods trial
- Author
-
South, Annabelle, Joharatnam-Hogan, Nalinie, Purvis, Cara, James, Elizabeth C., Diaz-Montana, Carlos, Cragg, William J., Tweed, Conor, Macnair, Archie, Sydes, Matthew R., Snowdon, Claire, Gillies, Katie, Isaacs, Talia, Bierer, Barbara E., and Copas, Andrew J.
- Subjects
Disclosure of information -- Methods ,Clinical trials -- Ethical aspects ,Chemotherapy -- Testing ,Cancer -- Chemotherapy ,Ovarian cancer -- Drug therapy ,Biological sciences - Abstract
Background Sharing trial results with participants is an ethical imperative but often does not happen. We tested an Enhanced Webpage versus a Basic Webpage, Mailed Printed Summary versus no Mailed Printed Summary, and Email List Invitation versus no Email List Invitation to see which approach resulted in the highest patient satisfaction with how the results were communicated. Methods and findings We carried out a cluster randomised, 2 by 2 by 2 factorial, nonblinded study within a trial, with semistructured qualitative interviews with some patients (ISRCTN96189403). Each cluster was a UK hospital participating in the ICON8 ovarian cancer trial. Interventions were shared with 384 ICON8 participants who were alive and considered well enough to be contacted, at 43 hospitals. Hospitals were allocated to share results with participants through one of the 8 intervention combinations based on random permutation within blocks of 8, stratified by number of participants. All interventions contained a written plain English summary of the results. The Enhanced Webpage also contained a short video. Both the Enhanced Webpage and Email contained links to further information and support. The Mailed Printed Summary was opt-out. Follow-up questionnaires were sent 1 month after patients had been offered the interventions. Patients' reported satisfaction was measured using a 5-point scale, analysed by ordinal logistic regression estimating main effects for all 3 interventions, with random effects for site, restricted to those who reported receiving the results and assuming no interaction. Data collection took place in 2018 to 2019. Questionnaires were sent to 275/384 randomly selected participants and returned by 180: 90/142 allocated Basic Webpage, 90/133 Enhanced Webpage; 91/141 no Mailed Printed Summary, 89/134 Mailed Printed Summary; 82/129 no Email List Invitation, 98/146 Email List Invitation. Only 3 patients opted out of receiving the Mailed Printed Summary; no patients signed up to the email list. Patients' satisfaction was greater at sites allocated the Mailed Printed Summary, where 65/81 (80%) were quite or very satisfied compared to sites with no Mailed Printed Summary 39/64 (61%), ordinal odds ratio (OR) = 3.15 (1.66 to 5.98, p < 0.001). We found no effect on patient satisfaction from the Enhanced Webpage, OR = 1.47 (0.78 to 2.76, p = 0.235) or Email List Invitation, OR = 1.38 (0.72 to 2.63, p = 0.327). Interviewees described the results as interesting, important, and disappointing (the ICON8 trial found no benefit). Finding out the results made some feel their trial participation had been more worthwhile. Regardless of allocated group, patients who received results generally reported that the information was easy to understand and find, were glad and did not regret finding out the results. The main limitation of our study is the 65% response rate. Conclusions Nearly all respondents wanted to know the results and were glad to receive them. Adding an opt-out Mailed Printed Summary alongside a webpage yielded the highest reported satisfaction. This study provides evidence on how to share results with other similar trial populations. Further research is needed to look at different results scenarios and patient populations. Trial registration ISRCTN: ISRCTN96189403., Author(s): Annabelle South 1,*, Nalinie Joharatnam-Hogan 1, Cara Purvis 1, Elizabeth C. James 1, Carlos Diaz-Montana 1, William J. Cragg 2, Conor Tweed 1, Archie Macnair 1, Matthew R. Sydes [...]
- Published
- 2021
- Full Text
- View/download PDF
9. Collaboration, participation and non-participation : decisions about involvement in randomised controlled trials for clinicians and parents in two neonatal trials
- Author
-
Snowdon, Claire and Elbourne, D.
- Subjects
615.10724 - Abstract
Background: The ethical basis of randomised controlled trials is equipoise, whether at the collective or individual level. Neonatal intensive care trials are therefore conducted in a context of clinical uncertainty as well as stress and trauma. The theoretical literature suggests that tensions exist in the trials situation between the aims of care and research. Objectives: To improve understanding of decisions that clinicians and parents make about neonatal trial collaboration, participation and non-participation. Methods: Semi-structured interviews were conducted with 30 neonatologists and 63 parents from 5 UK hospitals who were offered enrolment in the INNOVO and/or CANDA trials. Qualitative analysis was aided by ATLAS-ti. Results: The neonatologists' interviews suggested an intermediate level of equipoise. A therapeutic orientation operated for the INNOVO Trial but not for the CANDA Trial. Neonatologists often did not connect trial participation and trial-related postmortem pathology studies. Most parents made very rapid decisions about trial participation. Perception of risk was independent of the trial under consideration but associated with a slower decision-making process. The 'therapeutic misconception' was present for parents in both trials. Many supported contributing to research. For some of the bereaved parents, this extended to contribution to trial-related pathology studies. Parents who declined the CANDA Trial saw risks in the trial situation. Conclusions: Decisions were complex and multi-tiered. The boundaries between care and research were often unclear for neonatologists and parents. Clarification of the nature of decisions at the heart of clinical trials is needed, so that those associated with research might be willing collaborators and participants, fully cognisant of the activity in which they are engage
- Published
- 2005
- Full Text
- View/download PDF
10. Site staff perspectives on communicating trial results to participants: Cost and feasibility results from the Show RESPECT cluster randomised, factorial, mixed-methods trial.
- Author
-
South, Annabelle, Bailey, Julia, Bierer, Barbara E, Burnett, Eva, Cragg, William J, Diaz-Montana, Carlos, Gillies, Katie, Isaacs, Talia, Joharatnam-Hogan, Nalinie, Snowdon, Claire, Sydes, Matthew R, and Copas, Andrew J
- Subjects
CLUSTER sampling ,PILOT projects ,HUMAN research subjects ,PARTICIPANT-researcher relationships ,OVARIAN tumors ,CONFIDENCE intervals ,RESEARCH methodology ,PATIENT satisfaction ,INTERVIEWING ,REGRESSION analysis ,COST benefit analysis ,RANDOMIZED controlled trials ,COMPARATIVE studies ,COMMUNICATION ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,RESEARCH funding ,STATISTICAL sampling ,THEMATIC analysis - Abstract
Background/Aims: Sharing trial results with participants is an ethical imperative but often does not happen. Show RESPECT (ISRCTN96189403) tested ways of sharing results with participants in an ovarian cancer trial (ISRCTN10356387). Sharing results via a printed summary improved patient satisfaction. Little is known about staff experience and the costs of communicating results with participants. We report the costs of communication approaches used in Show RESPECT and the views of site staff on these approaches. Methods: We allocated 43 hospitals (sites) to share results with trial participants through one of eight intervention combinations (2 × 2 × 2 factorial; enhanced versus basic webpage, printed summary versus no printed summary, email list invitation versus no invitation). Questionnaires elicited data from staff involved in sharing results. Open- and closed-ended questions covered resources used to share results and site staff perspectives on the approaches used. Semi-structured interviews were conducted. Interview and free-text data were analysed thematically. The mean additional site costs per participant from each intervention were estimated jointly as main effects by linear regression. Results: We received questionnaires from 68 staff from 41 sites and interviewed 11 site staff. Sites allocated to the printed summary had mean total site costs of sharing results £13.71/patient higher (95% confidence interval (CI): −3.19, 30.60; p = 0.108) than sites allocated no printed summary. Sites allocated to the enhanced webpage had mean total site costs £1.91/patient higher (95% CI: −14, 18.74; p = 0.819) than sites allocated to the basic webpage. Sites allocated to the email list had costs £2.87/patient lower (95% CI: −19.70, 13.95; p = 0.731) than sites allocated to no email list. Most of these costs were staff time for mailing information and handling patients' queries. Most site staff reported no concerns about how they had shared results (88%) and no challenges (76%). Most (83%) found it easy to answer queries from patients about the results and thought the way they were allocated to share results with participants would be an acceptable standard approach (76%), with 79% saying they would follow the same approach for future trials. There were no significant effects of the randomised interventions on these outcomes. Site staff emphasised the importance of preparing patients to receive the results, including giving opt-in/opt-out options, and the need to offer further support, particularly if the results could confuse or distress some patients. Conclusions: Adding a printed summary to a webpage (which significantly improved participant satisfaction) may increase costs to sites by ~£14/patient, which is modest in relation to the cost of trials. The Show RESPECT communication interventions were feasible to implement. This information could help future trials ensure they have sufficient resources to share results with participants. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Adapting Patient and Public Involvement processes in response to the Covid‐19 pandemic.
- Author
-
Snowdon, Claire, Silver, Elizabeth, Charlton, Paul, Devlin, Brian, Greenwood, Emma, Hutchings, Andrew, Moug, Susan, Vohra, Ravinder, and Grieve, Richard
- Subjects
- *
MEETINGS , *PATIENT participation , *OPERATIVE surgery , *PATIENTS , *MEDICAL referrals , *RESEARCH funding , *PSYCHOLOGICAL adaptation , *STAY-at-home orders , *THEMATIC analysis , *COVID-19 pandemic - Abstract
Background: The COVID‐19 pandemic brought rapid and major changes to research, and those wishing to carry out Patient and Public Involvement (PPI) activities faced challenges, such as restrictions on movement and contact, illness, bereavement and risks to potential participants. Some researchers moved PPI to online settings during this time but remote consultations raise, as well as address, a number of challenges. It is important to learn from PPI undertaken in this period as face‐to‐face consultation may no longer be the dominant method for PPI. Methods: UK stay‐at‐home measures announced in March 2020 necessitated immediate revisions to the intended face‐to‐face methods of PPI consultation for the ESORT Study, which evaluated emergency surgery for patients with common acute conditions. PPI plans and methods were modified to all components being online. We describe and reflect on: initial plans and adaptation; recruitment; training and preparation; implementation, contextualisation and interpretation. Through first‐hand accounts we show how the PPI processes were developed, experienced and viewed by different partners in the process. Discussion and Conclusions: While concerns have been expressed about the possible limiting effects of forgoing face‐to‐face contact with PPI partners, we found important benefits from the altered dynamic of the online PPI environment. There were increased opportunities for participation which might encourage the involvement of a broader demographic, and unexpected benefits in that the online platform seemed to have a 'democratising' effect on the meetings, to the benefit of the PPI processes and outcomes. Other studies may however find that their particular research context raises particular challenges for the use of online methods, especially in relation to representation and inclusion, as new barriers to participation may be raised. It is important that methodological challenges are addressed, and researchers provide detailed examples of novel methods for discussion and empirical study. Patient and Public Contribution: We report a process which involved people with lived experience of emergency conditions and members of the public. A patient member was involved in the design and implementation, and two patients with lived experience contributed to the manuscript. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies
- Author
-
Batten, Leona M., Bhattacharya, Indrani Subarna, Moretti, Laura, Haviland, Joanne S., Emson, Marie A., Miller, Sarah E., Jefford, Monica, MacKenzie, Mairead, Wilcox, Maggie, Hyslop, Marie, Todd, Rachel, Snowdon, Claire F., and Bliss, Judith M.
- Published
- 2018
- Full Text
- View/download PDF
13. Information-hungry and disempowered: A qualitative study of women and their partners' experiences of severe postpartum haemorrhage
- Author
-
Snowdon, Claire, Elbourne, Diana, Forsey, Mary, and Alfirevic, Zarko
- Published
- 2012
- Full Text
- View/download PDF
14. Views of emergency research (VERA): A qualitative study of women and their partners' views of recruitment to trials in severe postpartum haemorrhage
- Author
-
Snowdon, Claire, Elbourne, Diana, Forsey, Mary, and Alfirevic, Zarko
- Published
- 2012
- Full Text
- View/download PDF
15. Clinical effectiveness and cost-effectiveness of emergency surgery for adult emergency hospital admissions with common acute gastrointestinal conditions: the ESORT study.
- Author
-
Grieve, Richard, Hutchings, Andrew, Zapata, Silvia Moler, O'Neill, Stephen, Lugo-Palacios, David G., Silverwood, Richard, Cromwell, David, Kircheis, Tommaso, Silver, Elizabeth, Snowdon, Claire, Charlton, Paul, Bellingan, Geoff, Moonesinghe, Ramani, Keele, Luke, Smart, Neil, and Hinchliffe, Robert
- Published
- 2023
- Full Text
- View/download PDF
16. Fifteen-minute consultation: an evidence-based approach to research without prior consent (deferred consent) in neonatal and paediatric critical care trials
- Author
-
Woolfall, Kerry, Frith, Lucy, Dawson, Angus, Gamble, Carrol, Lyttle, Mark D, Young, Bridget, Harris, Julia, Parker, Michael, Snowdon, Claire, Hickey, Helen, and Greig-Midlane, Hazel
- Published
- 2016
- Full Text
- View/download PDF
17. Trial Experience And Problems Of Parental Recollection Of Consent
- Author
-
Elbourne, Diana, Snowdon, Claire, Garcia, Jo, and Field, David
- Published
- 2001
18. Benefits and challenges of electronic data capture (EDC) systems versus paper case report forms
- Author
-
Malik, Ihtisham, Burnett, Stephanie, Webster-Smith, Mark, Morden, James, Ereira, Sharon, Gillman, Alexa, Lewis, Rebecca, Hall, Emma, Bliss, Judith, and Snowdon, Claire
- Published
- 2015
- Full Text
- View/download PDF
19. “You have to keep your nerve on a DMC.” Challenges for data monitoring committees in neonatal intensive care trials: qualitative accounts from the bracelet study
- Author
-
Snowdon, Claire, Elbourne, Diana, Brocklehurst, Peter, Platt, Martin Ward, and Tasker, Robert
- Published
- 2015
- Full Text
- View/download PDF
20. Design considerations when transitioning from paper case report forms (CRFS) to electronic data capture (EDC)
- Author
-
Lewis, Rebecca, Batten, Leona, Friend, Charlotte, Webster-Smith, Mark, Burnett, Stephanie, Morden, James, Hill, Elizabeth, Gillman, Alexa, Ereira, Sharon, Bliss, Judith, Hall, Emma, and Snowdon, Claire
- Published
- 2015
- Full Text
- View/download PDF
21. Implementing electronic data capture (EDC) training for site staff
- Author
-
Webster-Smith, Mark, Paulding, Claire, Burnett, Stephanie, Jeffs, Lisa, Ismail, Dalia, McNamara, Carolyn, Ereira, Sharon, Lewis, Rebecca, Hall, Emma, Bliss, Judith, and Snowdon, Claire
- Published
- 2015
- Full Text
- View/download PDF
22. Reactions of Participants to the Results of a Randomised Controlled Trial: Exploratory Study
- Author
-
Snowdon, Claire, Garcia, Jo, and Elbourne, Diana
- Published
- 1998
23. Informed Consent
- Author
-
Pfeffer, Naomi, Alderson, Priscilla, Campbell, Harry, Boyd, Kenneth M., Surry, Susan A. M., Cullinan, Tim, Squire, S. B., Hawley, R., Macfarlane, S., Agbaje, S., Beeching, N. J., Wyatt, G. B., De Koning, K., Gray, N., Hayward, C., Ali, A., Bianco, A. E., Taylor, M., Brabin, B., Coulter, J. B. S., de Burgh Daly, M., Elbourne, Diana, Snowdon, Claire, Garcia, Jo, Epstein, Keith, Sloat, Bill, Mohanna, Kay, Woodcock, Tom, Norman, John, Sikorski, Jim, Watson, Richard, Wilson, Philip, House, Allan, Knapp, Peter, Williamson, Charlotte, Sutton, Graham C., Garvican, Linda, Wilson, Robin, Malin, Adam, Lockwood, Diana, Mhlongo, S. W. P., Mdingi, G. V., Ashcroft, Richard, Toth, Ben, Mant, Jonathan, Winner, Simon, Carter, Judy, Wade, Derick T., Stott, D. J., Langhorne, P., Rodgers, H., Rutter, Deborah, Brewin, Thurstan, and Barer, David
- Published
- 1997
24. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study
- Author
-
Coleman, Robert E, Banks, Linda M, Girgis, Samia I, Kilburn, Lucy S, Vrdoljak, Eduard, Fox, John, Cawthorn, Simon J, Patel, Ashraf, Snowdon, Claire F, Hall, Emma, Bliss, Judith M, and Coombes, R Charles
- Published
- 2007
- Full Text
- View/download PDF
25. 'It was a snap decision': Parental and professional perspectives on the speed of decisions about participation in perinatal randomised controlled trials
- Author
-
Snowdon, Claire, Elbourne, Diana, and Garcia, Jo
- Subjects
Parenting -- Health aspects ,Health ,Social sciences - Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.socscimed.2005.10.008 Byline: Claire Snowdon, Diana Elbourne, Jo Garcia Keywords: Random controlled trials; Decision-making; Perinatal trials; Parents; United Kingdom Abstract: For some perinatal trials, parents can be asked to make important decisions about trial participation within limited timeframes in highly stressful circumstances. This qualitative study explores the pace of decision-making for 78 parents associated with one or more of four such trials in the UK. The themes associated with rapid decisions were concern for their baby, reactions to staff, and perceptions of the benefits and risks associated with the trial. Those who took longer to decide whether or not to participate often described similar emotions to those who made rapid decisions, but their slower decisions were because more time was available, they wanted further discussion or they found the decision particularly difficult. The majority of those who made rapid decisions felt that there were no risks associated with the trial in question, in contrast to the majority of those who made slower decisions who felt there were risks. The parents did not appear to view rapid decisions as problematic. Although there was evidence of parental vulnerability in each trial context, they largely felt that they acted swiftly and responsibly in the best interests of their child in accordance with the timeframes that were set for them. Author Affiliation: London School of Hygiene and Tropical Medicine, London, UK
- Published
- 2006
26. Using a theory-informed approach to explore patient and staff perspectives on factors that influence clinical trial recruitment for patients with cirrhosis and small oesophageal varices.
- Author
-
Le Boutillier, Clair, Snowdon, Claire, Patel, Vishal, McPhail, Mark, Ward, Christopher, Carter, Ben, Uddin, Ruhama, Zamalloa, Ane, and Lawrence, Vanessa
- Subjects
- *
PATIENT selection , *ESOPHAGEAL varices , *PATIENTS' attitudes , *PRAGMATICS , *CLINICAL trials , *CIRRHOSIS of the liver - Abstract
Objective: The success of pharmacological randomised controlled trials (RCTs) depends on the recruitment of the required number of participants. Recruitment to RCTs for patients with cirrhosis and small oesophageal varices raises specific additional challenges. The objectives of the study were 1) to explore patient perspectives on factors that influence RCT recruitment, 2) to understand factors that influence the success of recruitment from a staff perspective, and 3) to identify opportunities for tailored interventions to improve trial recruitment in this context. Methods: The qualitative study was embedded in a multi-centre blinded RCT (BOPPP trial) and was conducted alongside site opening. Semi-structured interviews were conducted with patients who enrolled to participate in the trial (n = 13), patients who declined to take part (n = 5), and staff who were responsible for recruiting participants to the trial (n = 18). An open approach to data collection and analysis was adopted and the Theoretical Domains Framework (TDF) was used to provide a theoretical lens through which to view influences on behaviour. Data was analysed using thematic analysis. Results: The findings consist of 5 overarching themes that outline trial recruitment influences at the patient, staff, team, organisational and trial levels: i) patient risks and benefits ii) staff attitudes, knowledge and capacity, iii) team-based approach, iv) organisational context and v) Trial collective. Patient-generated themes map onto thirteen of the fourteen TDF domains and staff-generated themes map onto all TDF domains. The overarching themes are not mutually exclusive; with evidence of direct interactions between patient and staff-level themes that influence recruitment behaviours. Conclusions: This study uses a theory-informed approach to gain new insights into improving clinical trial recruitment for patients with cirrhosis and small oesophageal varices. Although people with cirrhosis often display decreased healthcare-seeking behaviours, we found that patients used research to empower themselves to improve their health. Pragmatic trials involving unpredictable populations require staff expertise in building trust, and a deep knowledge of the patient group and their vulnerabilities. RCT recruitment is also more successful when research visits align with what staff identified as the natural rhythm of care. Trial registration: ISRCTN10324656; https://clinicaltrials.gov/. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Development of a standardised set of metrics for monitoring site performance in multicentre randomised trials: a Delphi study
- Author
-
Whitham, Diane, Turzanski, Julie, Bradshaw, Lucy, Clarke, Mike, Culliford, Lucy, Duley, Lelia, Shaw, Lisa, Skea, Zoe, Treweek, Shaun P., Walker, Kate, Williamson, Paula R., Montgomery, Alan A., Bevan, Simon, Devall, Adam, Fairbrother, Kathryn, Goodman, Kirsteen, Hewitt, Catherine, Hobson, Rachel, Lawton, Sarah, Lock, Stephen, McDonald, Alison, Norrie, John, Pearson, Sarah, Rhodes, Shelley, Snowdon, Claire, Thomas, Kim, and Wood, Jill
- Subjects
Trial management ,Performance metrics ,Consensus meeting ,Delphi survey ,Multicentre randomised trials - Abstract
BackgroundSite performance is key to the success of large multicentre randomised trials. A standardised set of clear and accessible summaries of site performance could facilitate the timely identification and resolution of potential problems, minimising their impact.The aim of this study was to identify and agree a core set of key performance metrics for managing multicentre randomised trials.MethodsWe used a mixed methods approach to identify potential metrics and to achieve consensus about the final set, adapting methods that are recommended by the COMET Initiative for developing core outcome sets in health care.We used performance metrics identified from our systematic search and focus groups to create an online Delphi survey. We invited respondents to score each metric for inclusion in the final core set, over three survey rounds. Metrics scored as critical by ?70% and unimportant by 50% of participants voting for inclusion were retained.ResultsRound 1 of the Delphi survey presented 28 performance metrics, and a further six were added in round 2. Of 294 UK-based stakeholders who registered for the Delphi survey, 211 completed all three rounds.At the consensus meeting, 17 metrics were discussed and voted on: 15 metrics were retained following survey round 3, plus two others that were preferred by consensus meeting participants. Consensus was reached on a final core set of eight performance metrics in three domains: (1) recruitment and retention, (2) data quality and (3) protocol compliance. A simple tool for visual reporting of the metrics is available from the Nottingham Clinical Trials Unit website.ConclusionsWe have established a core set of metrics for measuring the performance of sites in multicentre randomised trials. These metrics could improve trial conduct by enabling researchers to identify and address problems before trials are adversely affected. Future work could evaluate the effectiveness of using the metrics and reporting tool.
- Published
- 2018
28. Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer
- Author
-
Fallowfield, Lesley J., Bliss, Judith M., Porter, Lucy S., Price, Miranda H., Snowdon, Claire F., Jones, Stephen E., Coombes, R Charles, and Hall, Emma
- Published
- 2006
- Full Text
- View/download PDF
29. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
- Author
-
Coombes, R. Charles, Hall, Emma, Gibson, Lorna J., Paridaens, Robert, Jassem, Jacek, Delozier, Thierry, Jones, Stephen E., Alvarez, Isabel, Bertelli, Gianfilippo, Ortmann, Olaf, Coates, Alan S., Bajetta, Emilio, Dodwell, David, Coleman, Robert E., Fallowfield, Lesley J., Mickiewicz, Elizabeth, Andersen, Jorn, Lonning, Per E., Cocconi, Giorgio, Stewart, Alan, Stuart, Nick, Snowdon, Claire F., Carpentieri, Marina, Massimini, Giorgio, and Bliss, Judith M.
- Published
- 2004
- Full Text
- View/download PDF
30. The BRACELET Study: surveys of mortality in UK neonatal and paediatric intensive care trials
- Author
-
Platt Martin, Tasker Robert C, Brocklehurst Peter, Harvey Sheila E, Snowdon Claire, Allen Elizabeth, and Elbourne Diana
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background The subject of death and bereavement in the context of randomised controlled trials in neonatal or paediatric intensive care is under-researched. The objectives of this phase of the Bereavement and RAndomised ControlLEd Trials (BRACELET) Study were to determine trial activity in UK neonatal and paediatric intensive care (2002-06); numbers of deaths before hospital discharge; and variation in mortality across intensive care units and trials and to determine whether bereavement support policies were available within trials. These are essential prerequisites to considering the implications of future policies and practice subsequent to bereavement following a child's enrolment in a trial. Methods The units survey involved neonatal units providing level 2 or 3 care, and paediatric units providing level II care or above; the trials survey involved trials where allocation was randomized and interventions were delivered to intensive care patients, or to parents but designed to affect patient outcomes. Results Information was available from 191/220 (87%) neonatal units (149 level 2 or 3 care); and 28/32 (88%) paediatric units. 90/177 (51%) eligible responding units participated in one or more trial (76 neonatal, 14 paediatric) and 54 neonatal units and 6 paediatric units witnessed at least one death. 50 trials were identified (36 neonatal, 14 paediatric). 3,137 babies were enrolled in neonatal trials, 210 children in paediatric trials. Deaths ranged 0-278 (median [IQR interquartile range] 2 [1, 14.5]) per neonatal trial, 0-4 (median [IQR] 1 [0, 2.5]) per paediatric trial. 534 (16%) participants died post-enrolment: 522 (17%) in neonatal trials, 12 (6%) in paediatric trials. Trial participants ranged 1-236 (median [IQR] 21.5 [8, 39.8]) per neonatal unit, 1-53 (median [IQR] 11.5 [2.3, 33.8]) per paediatric unit. Deaths ranged 0-37 (median [IQR] 3.5 [0.3, 8.8]) per neonatal unit, 0-7 (median [IQR] 0.5 [0, 1.8]) per paediatric unit. Three trials had a formal policy for responding to bereavement. Conclusions A substantial number of deaths after trial enrolment were identified, distributed over many trials and units. Few trial teams had responses to bereavement in place. Those with the largest numbers of deaths might be best placed to collaborate in developing and assessing responses to bereavement.
- Published
- 2010
- Full Text
- View/download PDF
31. Control of hyperglycaemia in paediatric intensive care (CHiP): study protocol
- Author
-
Percy Deborah, Snowdon Claire, Allen Elizabeth, Betts Helen, Truesdale Ann, Goldman Allan, Slavik Zdenek, Fortune Peter-Marc, Baines Paul, Schindler Margrid, Nadel Simon, Parslow Roger, Grieve Richard, Pappachan John, Macrae Duncan, Broadhead Michael, Quick Tara, Peters Mark, Morris Kevin, Tasker Robert, and Elbourne Diana
- Subjects
Pediatrics ,RJ1-570 - Abstract
Abstract Background There is increasing evidence that tight blood glucose (BG) control improves outcomes in critically ill adults. Children show similar hyperglycaemic responses to surgery or critical illness. However it is not known whether tight control will benefit children given maturational differences and different disease spectrum. Methods/Design The study is an randomised open trial with two parallel groups to assess whether, for children undergoing intensive care in the UK aged ≤ 16 years who are ventilated, have an arterial line in-situ and are receiving vasoactive support following injury, major surgery or in association with critical illness in whom it is anticipated such treatment will be required to continue for at least 12 hours, tight control will increase the numbers of days alive and free of mechanical ventilation at 30 days, and lead to improvement in a range of complications associated with intensive care treatment and be cost effective. Children in the tight control group will receive insulin by intravenous infusion titrated to maintain BG between 4 and 7.0 mmol/l. Children in the control group will be treated according to a standard current approach to BG management. Children will be followed up to determine vital status and healthcare resources usage between discharge and 12 months post-randomisation. Information regarding overall health status, global neurological outcome, attention and behavioural status will be sought from a subgroup with traumatic brain injury (TBI). A difference of 2 days in the number of ventilator-free days within the first 30 days post-randomisation is considered clinically important. Conservatively assuming a standard deviation of a week across both trial arms, a type I error of 1% (2-sided test), and allowing for non-compliance, a total sample size of 1000 patients would have 90% power to detect this difference. To detect effect differences between cardiac and non-cardiac patients, a target sample size of 1500 is required. An economic evaluation will assess whether the costs of achieving tight BG control are justified by subsequent reductions in hospitalisation costs. Discussion The relevance of tight glycaemic control in this population needs to be assessed formally before being accepted into standard practice. Trial Registration Current Controlled Trials ISRCTN61735247
- Published
- 2010
- Full Text
- View/download PDF
32. Informed consent: Subjects may not understand concept of clinical trials
- Author
-
Elbourne, Diana, Snowdon, Claire, and Garcia, Jo
- Published
- 1997
33. Patient and public involvement prior to trial initiation: lessons learnt for rapid partnership in the COVID-19 era.
- Author
-
Jamal, Zahra, Perkins, Alexander, Allen, Christopher, Evans, Richard, Sturgess, Joanna, Snowdon, Claire, Clayton, Tim, and Elbourne, Diana
- Subjects
COVID-19 ,COVID-19 pandemic ,TROPICAL medicine ,PSYCHOLOGICAL feedback ,CLINICAL medicine ,CLINICAL trials - Abstract
Plain English summary: Patient and Public Involvement (PPI) describes the active involvement of patients and the public in the research process. Through PPI, patients and members of the public are increasingly involved in the design and conduct of clinical trials. PPI has been shown to improve the quality and relevance of research. During the COVID-19 pandemic, clinical trials have been playing a vital role in helping us find ways to prevent and treat the infection and improve our understanding of the virus. It is important that patients and the public are actively involved in deciding how COVID-19 research is carried out. Unfortunately, Research Ethics Committees in the UK have seen far less PPI for COVID-19 research studies compared with research before the pandemic. A key reason for this is that research is being designed much faster than normal and researchers may feel they do not have time to properly involve patients and the public. In this paper, we share our experiences of PPI for a COVID-19 clinical trial. We show that it is possible to rapidly involve patients and the public in COVID-19 clinical trials. We also explain how the design of the clinical trial was changed in response to feedback from public contributors. Lastly, we discuss the wider learning from this process which might be useful for researchers planning PPI activities for COVID-19 clinical trials in the future. Background: Clinical trials are playing a critical role in the global public health response to the COVID-19 pandemic. Despite the increasing recognition of the value of PPI in clinical trials, just 22% of the COVID-19 research proposals reviewed by Research Ethics Committees in the UK at the start of the pandemic reported PPI. There is a perception that PPI might result in delays in delivering research and therefore delays in obtaining important results. In this paper, we report our experience of rapid PPI for a COVID-19 clinical trial. Methods: RAPID-19 is a COVID-19 clinical trial which was planned to be submitted for fast-track ethics review in the United Kingdom. During the development of the trial protocol, the PPI Panel at the London School of Hygiene & Tropical Medicine Clinical Trials Unit was involved in the design of the study. The meeting with the PPI Panel lasted just over 1 h and was conducted by teleconference. Results: Although we only had a short period of time to explore the study with the PPI Panel, we were able to gain valuable insight into how the trial would be perceived by potential trial participants. Substantive changes were made to the trial to improve the acceptability of the research without compromising the study timelines. Having access to public contributors with relevant lived experience is an important resource for a Clinical Trials Unit and is critical for rapid PPI. The move to remote working due to lockdown required virtual discussions which helped to overcome some of the barriers to organising face-to-face meetings at short notice. Conclusions: PPI for clinical trials can be conducted in a time-efficient manner within the pressured environment of a pandemic. Involving PPI contributors at an early stage in protocol development maximised the opportunity to shape and influence the trial as well as limited potential delays which could occur if changes to the protocol had to be made at a later stage. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Marketing and clinical trials: a case study
- Author
-
Entwistle Vikki A, Snowdon Claire, Garcia Jo, Knight Rosemary C, Shakur Haleema, Elbourne Diana R, Roberts Ian, Francis David, McDonald Alison M, Grant Adrian M, and Campbell Marion K
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background Publicly funded clinical trials require a substantial commitment of time and money. To ensure that sufficient numbers of patients are recruited it is essential that they address important questions in a rigorous manner and are managed well, adopting effective marketing strategies. Methods Using methods of analysis drawn from management studies, this paper presents a structured assessment framework or reference model, derived from a case analysis of the MRC's CRASH trial, of 12 factors that may affect the success of the marketing and sales activities associated with clinical trials. Results The case study demonstrates that trials need various categories of people to buy in – hence, to be successful, trialists must embrace marketing strategies to some extent. Conclusion The performance of future clinical trials could be enhanced if trialists routinely considered these factors.
- Published
- 2007
- Full Text
- View/download PDF
35. Does it matter if clinicians recruiting for a trial don't understand what the trial is really about? Qualitative study of surgeons' experiences of participation in a pragmatic multi-centre RCT
- Author
-
Snowdon Claire, Featherstone Katie, Ziebland Sue, Barker Karen, Frost Helen, and Fairbank Jeremy
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background Qualitative methods are increasingly used to study the process of clinical trials and patients understanding of the rationale for trials, randomisation and reasons for taking part or refusing. Patients' understandings are inevitably influenced by the recruiting clinician's understanding of the trial, yet relatively little qualitative work has explored clinicians' perceptions and understandings of trials. This study interviewed surgeons shortly after the multi-centre, pragmatic RCT in which they had participated had been completed. Methods We used in-depth interviews with surgeons who participated in the Spine Stabilisation Trial (a pragmatic RCT) to explore their understanding of the trial purpose and how this understanding had influenced their recruitment procedures and interpretation of the results. A purposive sample of eleven participating surgeons was chosen from 8 of the 15 UK trial centres. Results Although the surgeons thought that the trial was addressing an important question there was little agreement about what this question was: although it was a trial of 'equivalent' treatments, some thought that it was a trial of surgery, others a trial of rehabilitation and others that it was exploring what to do with patients in whom all other treatment options had been unsuccessful. The surgeons we interviewed were not aware of the rationale for the pragmatic inclusion criteria and nearly all were completely baffled about the meaning of 'equipoise'. Misunderstandings about the entry criteria were an important source of confusion about the results and led to reluctance to apply the results to their own practice. Conclusion The study suggests several lessons for the conduct of future multi-centre trials. Recruiting surgeons (and other clinicians) may not be familiar with the rationale for pragmatic designs and may need to be regularly reminded about the purpose during the study. Reassurance may be necessary that a pragmatic design is not considered a design fault. We conclude that it does matter if clinicians do not understand the rationale for the trial if, as we have shown here, their perception of the trial aims and methods adversely affects who they recruit; if their views affect what the patients are told; and if they mistakenly view the results as unscientific, unreliable and ultimately irrelevant to their practice.
- Published
- 2007
- Full Text
- View/download PDF
36. Clinical trials and neonatal intensive care
- Author
-
ELBOURNE, DIANA, GARCIA, JO, and SNOWDON, CLAIRE
- Published
- 1995
37. Financial considerations in the conduct of multi-centre randomised controlled trials: evidence from a qualitative study
- Author
-
Grant Adrian M, Francis David, Entwistle Vikki A, Campbell Marion K, Garcia Jo, Elbourne Diana R, Snowdon Claire, Knight Rosemary C, McDonald Alison M, and Roberts Ian
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background Securing and managing finances for multicentre randomised controlled trials is a highly complex activity which is rarely considered in the research literature. This paper describes the process of financial negotiation and the impact of financial considerations in four UK multicentre trials. These trials had met, or were on schedule to meet, recruitment targets agreed with their public-sector funders. The trials were considered within a larger study examining factors which might be associated with trial recruitment (STEPS). Methods In-depth semi-structured telephone interviews were conducted in 2003–04 with 45 individuals with various responsibilities to one of the four trials. Interviewees were recruited through purposive and then snowball sampling. Interview transcripts were analysed with the assistance of the qualitative package Atlas-ti. Results The data suggest that the UK system of dividing funds into research, treatment and NHS support costs brought the trial teams into complicated negotiations with multiple funders. The divisions were somewhat malleable and the funding system was used differently in each trial. The fact that all funders had the potential to influence and shape the trials considered here was an important issue as the perspectives of applicants and funders could diverge. The extent and range of industry involvement in non-industry-led trials was striking. Three broad periods of financial work (foundation, maintenance, and resourcing completion) were identified. From development to completion of a trial, the trialists had to be resourceful and flexible, adapting to changing internal and external circumstances. In each period, trialists and collaborators could face changing costs and challenges. Each trial extended the recruitment period; three required funding extensions from MRC or HTA. Conclusion This study highlights complex financial aspects of planning and conducting trials, especially where multiple funders are involved. Recognition of the importance of financial stability and of the need for appropriate training in this area should be paralleled by further similar research with a broader range of trials, aimed at understanding and facilitating the conduct of clinical research.
- Published
- 2006
- Full Text
- View/download PDF
38. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies
- Author
-
Francis David, Elbourne Diana R, Cook Jonathan A, Grant Adrian M, Entwistle Vikki A, Campbell Marion K, Knight Rosemary C, McDonald Alison M, Garcia Jo, Roberts Ian, and Snowdon Claire
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background A commonly reported problem with the conduct of multicentre randomised controlled trials (RCTs) is that recruitment is often slower or more difficult than expected, with many trials failing to reach their planned sample size within the timescale and funding originally envisaged. The aim of this study was to explore factors that may have been associated with good and poor recruitment in a cohort of multicentre trials funded by two public bodies: the UK Medical Research Council (MRC) and the Health Technology Assessment (HTA) Programme. Methods The cohort of trials was identified from the administrative databases held by the two funding bodies. 114 trials that recruited participants between 1994 and 2002 met the inclusion criteria. The full scientific applications and subsequent trial reports submitted by the trial teams to the funders provided the principal data sources. Associations between trial characteristics and recruitment success were tested using the Chi-squared test, or Fisher's exact test where appropriate. Results Less than a third (31%) of the trials achieved their original recruitment target and half (53%) were awarded an extension. The proportion achieving targets did not appear to improve over time. The overall start to recruitment was delayed in 47 (41%) trials and early recruitment problems were identified in 77 (63%) trials. The inter-relationship between trial features and recruitment success was complex. A variety of strategies were employed to try to increase recruitment, but their success could not be assessed. Conclusion Recruitment problems are complex and challenging. Many of the trials in the cohort experienced recruitment difficulties. Trials often required extended recruitment periods (sometimes supported by additional funds). While this is of continuing concern, success in addressing the trial question may be more important than recruitment alone.
- Published
- 2006
- Full Text
- View/download PDF
39. Choice of baby's sex
- Author
-
Statham, Helen, Green, Josephine, Snowdon, Claire, and France-Dawson, Merry.
- Published
- 1993
40. Life After COVID-19 for Cancer Clinical Trials
- Author
-
Hall, Emma, Lewis, Rebecca, and Snowdon, Claire
- Published
- 2020
- Full Text
- View/download PDF
41. Mothers' Consent To Screening Newborn Babies For Disease
- Author
-
Statham, Helen, Green, Josephine, and Snowdon, Claire
- Published
- 1993
42. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
- Author
-
Johnston, Stephen, Puhalla, Shannon, Wheatley, Duncan, Ring, Alistair, Barry, Peter, Holcombe, Chris, Boileau, Jean Francois, Provencher, Louise, Robidoux, André, Rimawi, Mothaffar, McIntosh, Stuart A., Shalaby, Ibrahim, Stein, Robert C., Thirlwell, Michael, Dolling, David, Morden, James, Snowdon, Claire, Perry, Sophie, Cornman, Chester, and Batten, Leona M.
- Published
- 2019
- Full Text
- View/download PDF
43. "You have to keep your nerve on a DMC." Challenges for Data Monitoring Committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study.
- Author
-
Snowdon, Claire, Brocklehurst, Peter, Tasker, Robert C., Ward Platt, Martin, and Elbourne, Diana
- Subjects
- *
CLINICAL trials , *COMMUNITY-based clinical trials , *INVESTIGATIONAL therapies , *CRITICAL care medicine , *INTENSIVE care units - Abstract
Background: Data Monitoring Committees (DMCs) are essential to the good conduct of many trials. Typically they comprise a small expert group which monitors safety, efficacy, progress and early outcome data as trials recruit. DMCs can recommend protocol revisions and early stopping of a trial. As DMC meetings usually consider unblinded interim data confidentially, their deliberations are seldom exposed to research scrutiny. Although there have been some case studies from trials from mixed specialties which offer insights into some of the common issues faced by DMCs, we have, however, little empirical information about the challenges faced within specific clinical settings. Methods: In-depth interviews with participants in the BRACELET Study on death and bereavement in neonatal intensive care trials produced qualitative accounts of experiences and views of a subgroup of 18 DMC members. These interviews explored views of DMC members in relation to the clinical context of neonatal intensive care and the conduct of neonatal intensive care trials. Results: Interviewees felt that an understanding of both the neonatal intensive care setting and population was crucial in a DMC. They considered the neonatal intensive care research population especially vulnerable, and that outcomes that included both death and severe disability raised particular challenges rarely faced in other settings. In exploring these key outcomes they were mindful of the need to meet high scientific standards and the needs of babies in the trials and their families. DMC members discussed particular difficulties around the composite outcome of death and severe disability, especially when mortality data were available long before data on longer term disability. While statistical stopping guidance is helpful, DMC members described decisions about stopping, revising or continuing a trial being informed by a wider set of considerations and discussions than a pre-set p value. These included potentially competing needs of current trial participants and future patients, and reflections on the nature of benefit and harm. Given their cognisance of the potential impact and consequences of the decisions made by DMCs in this setting of life, death, and disability, interviewees commonly used the imagery of bravery, and described DMCs either holding or losing their nerve. Conclusions: DMCs for trials in other fields may also face difficult ethical trade-offs in monitoring composite outcomes. The experience from this sample of DMC members suggest that for neonatal intensive care trials there are some very specific challenges seldom faced elsewhere. The vulnerability of the population, and the different timescales for essential data becoming available to inform decisions, presented particular challenges. We suggest that it is important to consider the challenges raised in other settings to better understand the complex work of these committees and to prepare future generations of DMC members. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
44. Conducting non-commercial international clinical trials: the ICR-CTSU experience.
- Author
-
Fox, Lisa, Toms, Christy, Kernaghan, Sarah, Snowdon, Claire, and Bliss, Judith M.
- Subjects
CLINICAL trials ,CANCER treatment ,CANCER research ,CANCER patients ,RESEARCH & economics ,ANTINEOPLASTIC agents ,ENDOWMENT of research ,EXPERIMENTAL design ,INTERNATIONAL relations ,MEDICAL care costs ,MEDICAL cooperation ,POLICY sciences ,RESEARCH ,TUMORS ,TREATMENT effectiveness ,INSTITUTIONAL cooperation ,ECONOMICS - Abstract
Background: Academic clinical trials play a fundamental role in the development of new treatments, the repurposing of existing treatments and in addressing areas of unmet clinical need. With cancer treatments increasingly targeted at molecular subtypes, and with priority placed on developing new treatments for rare tumour types, the need for international trial participation to access sufficient patient numbers for successful trial conduct is growing. However, lack of harmonisation of international legal, ethical and financial systems can make this challenging and the cost and effort of conducting trials internationally can be considered prohibitive, particularly where the sample size is comparatively small.Methods: The Institute of Cancer Research - Clinical Trials and Statistics Unit (ICR-CTSU) is a UK-based academic clinical trials unit that specialises in the design, conduct and analysis of clinical trials of cancer treatments with an expanding portfolio of trials in molecular subtypes of breast and urological cancers and in other rare cancer types. Implementing appropriate mechanisms to enable international participation has therefore been imperative. In this article, we explain how we have approached the challenges involved and describe examples of successful international trial conduct, achieved through robust collaborations with academic and industry partners.Conclusion: Conducting academic trials internationally is challenging but can and should be achieved through appropriate governance mechanisms and strong collaborations. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
45. Long-Term Follow-Up of the Intergroup Exemestane Study.
- Author
-
Morden, James P., Alvarez, Isabel, Bertelli, Gianfilippo, Coates, Alan S., Coleman, Robert, Fallowfield, Lesley, Jassem, Jacek, Jones, Stephen, Kilburn, Lucy, Lønning, Per E., Ortmann, Olaf, Snowdon, Claire, van de Velde, Cornelis, Andersen, Jørn, Del Mastro, Lucia, Dodwell, David, Holmberg, Stig, Nicholas, Hanna, Paridaens, Robert, and Bliss, Judith M.
- Published
- 2017
- Full Text
- View/download PDF
46. The role of therapeutic optimism in recruitment to a clinical trial in a peripartum setting: balancing hope and uncertainty.
- Author
-
Hallowell, Nina, Snowdon, Claire, Morrow, Susan, Norman, Jane E., Denison, Fiona C., and Lawton, Julia
- Subjects
- *
CLINICAL trials , *PERIPARTUM cardiomyopathy , *EXERCISE therapy , *NITROGLYCERIN , *MEDICAL care , *CHILDBIRTH , *EXPERIMENTAL design , *UNCERTAINTY , *QUALITATIVE research , *PATIENT selection - Abstract
Background: Hope has therapeutic value because it enables people to cope with uncertainty about their future health. Indeed, hope, or therapeutic optimism (TO), is seen as an essential aspect of the provision and experience of medical care. The role of TO in clinical research has been briefly discussed, but the concept, and whether it can be transferred from care to research and from patients to clinicians, has not been fully investigated. The role played by TO in research emerged during interviews with staff involved in a peripartum trial. This paper unpacks the concept of TO in this setting and considers the role it may play in the wider delivery of clinical trials.Methods: The Got-it trial is a UK-based, randomised placebo-controlled trial that investigates the use of sublingual glyceryl trinitrate (GTN) spray to treat retained placenta. Qualitative data were collected in open-ended interviews with obstetricians, research and clinical midwives (n =27) involved in trial recruitment. Data were analysed using the method of constant comparison.Results: TO influenced staff engagement with Got-it at different points in the trial and in different ways. Prior knowledge of, and familiarity with, GTN meant that from the outset staff perceived the trial as low risk. TO facilitated staff involvement in the trial; staff who already understood GTN's effects were optimistic that it would work, and staff collaborated because they hoped that the trial would address what they identified as an important clinical need. TO could fluctuate over the course of the trial, and was sustained or undermined by unofficial observation of clinical outcomes and speculations about treatment allocation. Thus, TO appeared to be influenced by key situational factors: prior knowledge and experience, clinical need and observed participant outcomes.Conclusions: Situational TO plays a role in facilitating staff engagement with clinical research. TO may affect trial recruitment by enabling staff to sustain the levels of uncertainty, or individual equipoise, necessary to collaborate with research while also responding to patients' clinical needs. Staff may benefit from training to deal with fluctuations in TO.Trial Registration: ISCRTN88609453 . Registered on 26 March 2014. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
47. Recruiting and consenting into a peripartum trial in an emergency setting: a qualitative study of the experiences and views of women and healthcare professionals.
- Author
-
Lawton, Julia, Snowdon, Claire, Morrow, Susan, Norman, Jane E., Denison, Fiona C., and Hallowell, Nina
- Subjects
- *
CLINICAL trials , *PERIPARTUM cardiomyopathy , *PREGNANCY complications , *PATIENT-professional relations , *PATIENT participation , *ATTITUDE (Psychology) , *COMPARATIVE studies , *DECISION making , *EMERGENCY medical services , *HEALTH attitudes , *INFORMED consent (Medical law) , *INTERVIEWING , *LABOR complications (Obstetrics) , *RESEARCH methodology , *MEDICAL cooperation , *MEDICAL personnel , *SENSORY perception , *PLACENTA diseases , *READABILITY (Literary style) , *RESEARCH , *STATISTICAL sampling , *QUALITATIVE research , *PILOT projects , *EVALUATION research , *RANDOMIZED controlled trials , *BLIND experiment , *PATIENT selection , *PSYCHOLOGY of human research subjects , *DIAGNOSIS - Abstract
Background: Recruiting and consenting women to peripartum trials can be challenging as the women concerned may be anxious, in pain, and exhausted; there may also be limited time for discussion and decision-making to occur. To address these potential difficulties, we undertook a qualitative evaluation of the internal pilot of a trial (Got-it) involving women who had a retained placenta (RP). We explored the experiences and views of women and staff about the information and consent pathway used within the pilot, in order to provide recommendations for use in future peripartum trials involving recruitment in emergency situations.Methods: In-depth interviews were undertaken with staff (n = 27) and participating women (n = 22). Interviews were analysed thematically. The accounts of women and staff were compared to identify differences and similarities in their views about recruitment and consent procedures.Results: Women and staff regarded recruitment as having been straightforward and facilitated by the use of simplified (verbal and written) summaries of trial information. Both parties, however, conveyed discordant views about whether fully informed consent had been obtained. These differences in perspectives appeared to arise from the different factors and considerations impinging on women and staff at the time of recruitment. While staff placed emphasis on promoting understanding in the emergency situation of RP by imparting information in clear and succinct ways, women highlighted the experiential realities of their pre- and post-birthing situations, and how these had led to quick decisions being made without full engagement with the potential risks of trial participation. To facilitate informed consent, women suggested that trial information should be given during the antenatal period, and, in doing so, articulated a rights-based discourse. Staff, however, voiced opposition to this approach by emphasising a duty of care to all pregnant women, and raising concerns about causing undue distress to the majority of individuals who would not subsequently develop a RP.Conclusions: By drawing upon the perspectives of women and staff involved in the same trial we have shown that they may operate within different experiential and ethical paradigms. In doing so, we argue for the potential benefits of drawing upon multiple perspectives when developing information and consent pathways used in future (peripartum) trials.Trial Registration: ISCRTN 88609453 . [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
48. First steps: study protocol for a randomized controlled trial of the effectiveness of the Group Family Nurse Partnership (gFNP) program compared to routine care in improving outcomes for high-risk mothers and their children and preventing abuse.
- Author
-
Barnes, Jacqueline, Aistrop, Dipti, Allen, Elizabeth, Barlow, Jane, Elbourne, Diana, Macdonald, Geraldine, Melhuish, Edward, Petrou, Stavros, Pink, Joshua, Snowdon, Claire, Spiby, Helen, Stuart, Jane, and Sturgess, Joanna
- Subjects
CLINICAL trials ,DOMESTIC violence ,FAMILY nursing ,CHILD abuse ,MENTAL illness ,ENGLISH language ,MENSTRUAL cycle - Abstract
Background: Evidence from the USA suggests that the home-based Family Nurse Partnership program (FNP), extending from early pregnancy until infants are 24 months, can reduce the risk of child abuse and neglect throughout childhood. FNP is now widely available in the UK. A new variant, Group Family Nurse Partnership (gFNP) offers similar content but in a group context and for a shorter time, until infants are 12 months old. Each group comprises 8 to 12 women with similar expected delivery dates and their partners. Its implementation has been established but there is no evidence of its effectiveness. Methods/Design: The study comprises a multi-site randomized controlled trial designed to identify the benefits of gFNP compared to standard care. Participants (not eligible for FNP) must be either aged < 20 years at their last menstrual period (LMP) with one or more previous live births, or aged 20 to 24 at LMP with low educational qualifications and no previous live births. 'Low educational qualifications' is defined as not having both Maths and English Language GCSE at grade C or higher or, if they have both, no more than four in total at grade C or higher. Exclusions are: under 20 years and previously received home-based FNP and, in either age group, severe psychotic mental illness or not able to communicate in English. Consenting women are randomly allocated (minimized by site and maternal age group) when between 10 and 16 weeks pregnant to either to the 44 session gFNP program or to standard care after the collection of baseline information. Researchers are blind to group assignment. The primary outcomes at 12 months are child abuse potential based on the revised Adult-Adolescent Parenting Inventory and parent/infant interaction coded using the CARE Index based on a video-taped interaction. Secondary outcomes are maternal depression, parenting stress, health related quality of life, social support, and use of services Discussion: This is the first study of the effectiveness of gFNP in the UK. Results should inform decision-making about its delivery alongside universal services, potentially enabling a wider range of families to benefit from the FNP curriculum and approach to supporting parenting. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
49. What Parents of Children Who Have Received Emergency Care Think about Deferring Consent in Randomised Trials of Emergency Treatments: Postal Survey.
- Author
-
Gamble, Carrol, Nadel, Simon, Snape, Dee, McKay, Andrew, Hickey, Helen, Williamson, Paula, Glennie, Linda, Snowdon, Claire, and Young, Bridget
- Subjects
EMERGENCY medical services ,MENINGITIS ,EMERGENCY medicine ,MEDICAL care ,CLINICAL trials ,CHILD mortality ,PATIENTS - Abstract
Objective: To investigate parents' views about deferred consent to inform management of trial disclosure after a child's death. Methods: A postal questionnaire survey was sent to members of the Meningitis Research Foundation UK charity, whose child had suffered from bacterial meningitis or meningococcal septicaemia within the previous 5 years. Main outcome measures were acceptability of deferred consent; timing of requesting consent; and the management of disclosure of the trial after a child's death. Results: 220 families were sent questionnaires of whom 63 (29%) were bereaved. 68 families responded (31%), of whom 19 (28%) were bereaved. The majority (67%) was willing for their child to be involved in the trial without the trial being explained to them beforehand; 70% wanted to be informed about the trial as soon as their child's condition had stabilised. In the event of a child's death before the trial could be discussed the majority of bereaved parents (66% 12/18) anticipated wanting to be told about the trial at some time. This compared with 37% (18/49) of non-bereaved families (p = 0.06). Parents' free text responses indicated that the word 'trial' held strongly negative connotations. A few parents regarded gaps in the evidence base about emergency treatments as indicating staff lacked expertise to care for a critically ill child. Bereaved parents' free text responses indicated the importance of individualised management of disclosure about a trial following a child's death. Discussion: Deferred consent is acceptable to the majority of respondents. Parents whose children had recovered differed in their views compared to bereaved parents. Most bereaved parents would want to be informed about the trial in the aftermath of a child's death, although a minority strongly opposed such disclosure. Distinction should be drawn between the views of bereaved and non-bereaved parents when considering the acceptability of different consent processes. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
50. Parents' attitudes to neonatal research involving venepuncture.
- Author
-
Berrington, Janet E., Snowdon, Claire, and Fenton, Alan C.
- Subjects
- *
PARENT attitudes , *HEALTH surveys , *VENOUS puncture , *IMMUNIZATION , *MATERNALLY acquired immunity - Abstract
The objective of the study was to explore parental experiences of being offered participation in a previous neonatal research study involving venepuncture. The method employed was a questionnaire-based exploration of parents' attitudes in those approached to participate in a study of term and preterm immunization responses (Preterm Immunisation Study [PREMIS]). We explored experience of the initial approach, knowledge of study, venepuncture and views on research 'in general'. In all, 59% of families responded. Highest response rates were for those participating in PREMIS (87% term/69% preterm) and lowest in decliners (34%and 35%). Responding parents participating in PREMIS were well informed, positive about research and did not find the venepuncture problematic. Sixty percent of responding parents who declined PREMIS attributed their declining to the need for venepuncture. In conclusion, parents participating or declining a neonatal study involving venepuncture are different, but participating parents were well informed and seemed able to judge that participation was right for them such that in consenting families venepuncture itself is not problematic. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.